These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29404874)

  • 21. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yan BP; Yu CM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients.
    Mincu RI; Mahabadi AA; Totzeck M; Rassaf T
    Sci Rep; 2019 Feb; 9(1):3011. PubMed ID: 30816247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin K Antagonists Versus Novel Oral Anticoagulants for Elective Electrical Cardioversion of Atrial Fibrillation.
    Ţînţ D; Petriş AO; Pop I; Melnic R; Ignat AM; Rogozea LM
    Am J Ther; 2017; 24(5):e553-e558. PubMed ID: 28661896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation.
    Briasoulis A; Kottam A; Khan M; Afonso L
    J Thromb Thrombolysis; 2015 Aug; 40(2):139-43. PubMed ID: 25542262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.
    Liew A; O'Donnell M; Douketis J
    J Thromb Haemost; 2014 Sep; 12(9):1419-24. PubMed ID: 24986568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation.
    Benetos G; Bonou M; Toutouzas K; Diamantopoulos P; Viniou N; Barbetseas J
    Hamostaseologie; 2017 Oct; 37(4):277-285. PubMed ID: 28289746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
    Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
    Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.
    Rong F; Jia B; Huang P; Lynn HS; Zhang W
    Thromb Res; 2015 Jun; 135(6):1117-23. PubMed ID: 25891842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
    Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
    Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
    Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
    Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
    JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target-specific oral anticoagulants in patients undergoing cardioversion.
    Law EH; Gordon W
    Am J Health Syst Pharm; 2014 Jul; 71(14):1171-6. PubMed ID: 24973374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis.
    Gao X; Huang D; Hu Y; Chen Y; Zhang H; Liu F; Luo J
    Front Cardiovasc Med; 2022; 9():833329. PubMed ID: 35615562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature.
    Dentali F; Sironi AP; Gianni M; Orlandini F; Guasti L; Grandi AM; Franchini M; Ageno W; Squizzato A
    Semin Thromb Hemost; 2015 Oct; 41(7):774-87. PubMed ID: 26408921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.